Please login to the form below
Roche files patent lawsuit against Teva for osteoporosis drug
Roche files a lawsuit against generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment, Boniva
Swiss pharmaceutical company Roche has filed a lawsuit against Israel-headquartered generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment Boniva (ibandronate).
A Roche spokesperson said the lawsuit was instituted to prevent Teva from marketing a generic version of Boniva 150 mg tablets. The basic patent runs until 2012, with further patents protecting the drug until 2023.
Boniva recorded sales of CHF 374m (USD 315.7m) in H1 FY07, according to Roche.
Share
Related Hub content
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
